Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinicopathological characteristics of patient samples and expression of FLOT2 in breast cancer patients and correlation between FLOT2 expression and clinicopathological characteristics of breast cancer patients

From: Flotillin-2 is associated with breast cancer progression and poor survival outcomes

Characteristics Total (n = 171) FLOT2 chi-square test P-value Fisher’s exact test P-value
Low expression 50.0% High expression 50.0%
Age(y) ≥47 85 47(55.3) 38(44.7) 0.398 0.445
<47 86 42(48.8) 44(51.2)   
Clinical stage I 21 16(76.2) 5(23.8) <0.001 <0.001
II 92 53(57.6) 39(42.4)   
III 46 20(43.5) 26(56.5)   
IV 12 0(0.0) 12(100.0)   
T classification T1 35 26(74.3) 9(25.7) <0.001 <0.001
T2 89 51(57.3) 38(42.7)   
T3 35 11(31.4) 24(68.6)   
T4 12 1(8.3) 11(91.7)   
N classification N0 70 41(58.6) 29(41.4) 0.419 0.431
N1 65 33(50.8) 32(49.2)   
N2 27 11(40.7) 16(59.3)   
N3 9 4(44.4) 5(55.6)   
M classification Yes 12 0(0.0) 12(100.0) <0.001 <0.001
No 159 89(56.0) 70(44.0)   
Histological differentiation Well 9 6(66.7) 3(33.3) 0.005 0.005
Moderate 113 67(59.3) 46(40.7)   
Poor 49 16(32.7) 33(67.3)   
Expression of ER 0 77 38(49.4) 39(50.6) 0.155 0.165
1 82 41(50.0) 41(50.0)   
2 8 7(87.5) 1(12.5)   
3 4 3(75.0) 1(25.0)   
Expression of PR 0 71 35(49.3) 36(50.7) 0.498 0.527
1 80 41(51.2) 39(48.8)   
2 16 11(68.8) 5(31.2)   
3 3 1(33.3) 2(66.7)   
4 1 1(100.0) 0(0.0)   
Expression of ErbB-2 0 42 30(71.4) 12 (28.6) 0.003 0.002
1 52 30(57.7) 22(42.3)   
2 38 18(47.4) 20(52.6)   
3 30 9(30.0) 21(70.0)   
4 9 2(22.2) 7(77.8)